Plural Compounds Containing Cyclopentanohydrophenanthrene Ring Systems Patents (Class 514/170)
-
Publication number: 20130172300Abstract: A method of preventing estrogen deficiencies and osteoporosis in menopausal women by continuously orally administering without interruption to menopausal women in need thereof an amount of 0.3 to 3 mg of 17?-estradiol or esters thereof and 0.3 to 1.25 mg of nomegestrol or esters thereof in an amount sufficient to prevent said problems.Type: ApplicationFiled: April 17, 2012Publication date: July 4, 2013Inventors: Jacques Paris, Jean-Louis Thomas
-
Patent number: 8475838Abstract: A rapidly-dissolving oral dosage pharmaceutical composition for inhibiting ovulation in a mammal, said composition comprising drospirenone or a pharmaceutically acceptable salt or ester thereof, optionally ethinyl estradiol or a pharmaceutically acceptable salt, ester or ether thereof, a surfactant and at least one pharmaceutically acceptable excipient, wherein the drospirenone has a surface area of less than 10,000 cm2/g.Type: GrantFiled: June 3, 2005Date of Patent: July 2, 2013Assignee: Sandoz AGInventors: Pablo Davila, Paola Henar Paniagua Marcos, Benito Lorenzo Pajuelo
-
Publication number: 20130157988Abstract: The disclosure relates to novel C4 and C6 substituted androst-4-ene diones as well as andros-1,4-diene diones and derivatives thereof, their process of preparation, pharmaceutical compounds containing them, and the use of said compounds for the treatment of hormone-related disorders in mammals. This includes hormone-dependent cancers, particularly those caused by elevated levels of estrogen and its intermediates. These compounds can also be used in the treatment of other hormone-related disorders, including benign prostatic hyperplasia, cardiovascular disease, and neurodegenerative disorders.Type: ApplicationFiled: April 7, 2011Publication date: June 20, 2013Applicants: EMORY UNIVERSITY, HAUPTMAN-WOODWARD MEDICAL RESEARCH INSTITUTE, THE RESEARCH FOUNDATION OF STATE OF NEW YORKInventors: Huw Davies, Debashis Ghosh, Daniel Morton
-
Patent number: 8466134Abstract: The present invention provides compositions containing corticosteroid compounds as active agents for the treatment of ailments and diseases of the respiratory tract, particularly the lungs, by way of nasal and pulmonary administration. The corticosteroid compounds are present in a dissolved state in the compositions. The compositions can be formulated in a concentrated, essentially non-aqueous form for storage or in a diluted, aqueous-based form for ready delivery. In a preferred embodiment, the corticosteroid composition contains an ethoxylated derivative of vitamin E and/or a polyethylene glycol fatty acid ester as the high-HLB surfactant present in the formulation. The compositions are ideally suited for inhaled delivery with a nebulizer or for nasal delivery.Type: GrantFiled: June 24, 1999Date of Patent: June 18, 2013Assignee: Athena Neurosciences, Inc.Inventors: Zahir Saidi, Boris Klyashchitsky
-
Patent number: 8461138Abstract: A quadraphasic estrogenic/progestogenic contraceptive regimen that provides for a low level of estrogen in the initial phase and in the fourth phase is disclosed. Also described is a contraceptive kit that may be used to practice the method of the invention.Type: GrantFiled: June 29, 2006Date of Patent: June 11, 2013Assignee: Warner Chilcott Company, LLCInventor: Roger M. Boissonneault
-
Publication number: 20130143847Abstract: The present disclosure relates generally to methods and compositions for treating symptoms of Parkinson's disease and/or other movement disorders. More particularly, the present disclosure describes a method for treating symptoms of Parkinson's disease and related disorders by administering a composition comprising one or more of the following active agents; estradiol, estriol, testosterone, and 19-nortestosterone. In addition, the compositions of the present invention can be used for enhancing or optimizing the effectiveness of neural stimulation in treating the symptoms of movement disorders such as Parkinson's disease.Type: ApplicationFiled: November 19, 2012Publication date: June 6, 2013Inventor: Ellis L. Kline
-
Publication number: 20130140210Abstract: The present invention relates to a low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.5 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the low E2 and DRSP doses it has surprisingly been found that a very high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.Type: ApplicationFiled: April 12, 2011Publication date: June 6, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Stephan Mletzko, Rolf Schürmann, Kerstin Gude
-
Publication number: 20130142838Abstract: Compositions, preferably pharmaceutical compositions, containing micronized tanaproget, or pharmaceutically acceptable salt thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, butylated hydroxyanisole, povidone, and magnesium stearate, are provided. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic to disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake.Type: ApplicationFiled: November 29, 2012Publication date: June 6, 2013Applicant: Wyeth LLCInventor: Wyeth LLC
-
Patent number: 8455468Abstract: Methods of treating a subject with a traumatic central nervous system injury, more particularly, a traumatic brain injury, are provided. The methods comprise a therapy comprising a constant or a two-level dosing regime of progesterone. In one method, a subject in need thereof is administered at least one cycle of therapy, wherein the cycle of therapy comprises administering a therapeutically effective two-level intravenous dosing regime of progesterone. The two-level dosing regime comprises a first time period, wherein a higher hourly dose of progesterone is administered to the subject, followed by a second time period, wherein a lower hourly dose of progesterone is administered to the subject.Type: GrantFiled: March 10, 2011Date of Patent: June 4, 2013Assignee: Emory UniversityInventors: Stuart W. Hoffman, Arthur L. Kellermann, Donald G Stein, David W. Wright, Douglas W. Lowery-North
-
Publication number: 20130137648Abstract: Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols are useful as inhibitors of the phosphodiesterase 4 (PDE4) enzyme.Type: ApplicationFiled: January 23, 2013Publication date: May 30, 2013Applicant: Chiesi Farmaceutici S.p.A.Inventor: Chiesi Farmaceutici S.p.A.
-
Publication number: 20130137664Abstract: The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP doses it has surprisingly been found that a high proportion of the women suffering from moderate to severe hot flushes actually respond to this treatment. Accordingly, the dosage form of the invention may be used as maintenance HRT or may be used already when HRT is initiated.Type: ApplicationFiled: April 12, 2011Publication date: May 30, 2013Applicant: BAYER INTELLECTUAL PROPERTY GMBHInventors: Stephan Mletzko, Rolf Schürmann, Kerstin Gude
-
Patent number: 8450312Abstract: The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, magnesium stearate, micronized edetate calcium disodium hydrous, and micronized sodium thiosulfate pentahydrate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake.Type: GrantFiled: April 1, 2010Date of Patent: May 28, 2013Assignee: Wyeth LLCInventors: Arwinder S. Nagi, Ramarao Chatlapalli, Shamim Hasan, Mohamed Ghorab, Dhaval Gaglani
-
Patent number: 8450299Abstract: The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered to a female to provide contraceptive and non-contraceptive benefits.Type: GrantFiled: June 8, 2012Date of Patent: May 28, 2013Assignee: Teva Womans's Health, Inc.Inventors: Charles E. Diliberti, Kathleen Z. Reape, Lance J. Bronnenkant
-
Publication number: 20130131024Abstract: The present invention provides methods and compositions for the treatment of fluid accumulation in and/or under the retina.Type: ApplicationFiled: May 10, 2011Publication date: May 23, 2013Applicant: INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Francine Behar-Cohen, Nicolette Farman, Frederic Jaisser
-
Publication number: 20130131025Abstract: A neutral-fat-level-regulating agent, a cholesterol-level-regulating agent, a free-fatty-acid-level-regulating agent or an anti-obesity agent, including: at least one of protopanaxatriol, panaxatriol, protopanaxadiol and panaxadiol which are aglycons of dammarane-type saponins and a hyperlipemia-ameliorating agent including: at least one of the neutral-fat-level-regulating agent, the cholesterol-level-regulating agent, the free-fatty-acid-level-regulating agent and the anti-obesity agent.Type: ApplicationFiled: January 10, 2013Publication date: May 23, 2013Applicant: LION CORPORATIONInventors: Hiroaki Kambayashi, Kumiko Kitamura, Hideaki Iwasaki
-
Publication number: 20130129818Abstract: Estrogen and progesterone replacement therapies are provided herein. Among others, the following formulations are provided herein: solubilized estradiol without progesterone; micronized progesterone without estradiol; micronized progesterone with partially solubilized progesterone; solubilized estradiol with micronized progesterone; solubilized estradiol with micronized progesterone in combination with partially solubilized progesterone; and solubilized estradiol with solubilized progesterone.Type: ApplicationFiled: November 21, 2012Publication date: May 23, 2013Applicant: TherapeuticsMD, Inc.Inventor: TherapeuticsMD, Inc.
-
Publication number: 20130123219Abstract: The 15?,16?-methylene-17-hydroxy-19-nor-17-pregna-4-en-3-one-21-carboxylic acid ?-lactone derivatives of the present invention possess progestational efficacy. They have the general chemical formula I, in which Z is selected from the group comprising an oxygen atom, two hydrogen atoms, NOR and NNHSO2R, where R is hydrogen, C1-C10-alkyl, aryl or C7-C20-aralkyl, R4 is hydrogen or halogen, and moreover either: R6a, R6b together form methylene or 1,2-ethanediyl or R6a is hydrogen and R6b is selected from the group comprising hydrogen, C1-C10-alkyl, C2-C10-alkenyl or C2-C10-alkynyl, and R7 is selected from the group comprising hydrogen, C1-C10-alkyl, C3-C6-cycloalkyl, C2-C10-alkenyl or C2-C10-alkynyl, or: R6a is hydrogen and R6b and R7, together, denote a bond, an oxygen or form methylene, R18 represents hydrogen or C1-C3-alkyl and in addition include their solvates, hydrates, stereoisomers and salts.Type: ApplicationFiled: January 10, 2013Publication date: May 16, 2013Applicant: BAYER INTELLECTUAL PROPERTY GmbHInventor: BAYER INTELLECTUAL PROPERTY GmbH
-
Publication number: 20130123220Abstract: The present invention is directed to a suitable topical composition for cosmetic, pharmaceutical or dermatological use. In a particular aspect, it is a stable nanoemulsion whose particles have a narrow size distribution range. In another particular aspect, the invention is directed to an improved process for producing said composition.Type: ApplicationFiled: July 21, 2011Publication date: May 16, 2013Applicant: EVIDENCE SOLUÇÕES FARMACÊUTICAS LTDA EPPInventor: Dinalva Brito de Queiroz
-
Publication number: 20130116217Abstract: Methods for treating neurodegeneration and/or myelination in patients are disclosed comprising treating the patient with a progestin compound which exerts binding to progesterone receptors and elicits progesterone-receptor-induced biological responses without interacting with the androgen receptor and without inducing androgen or glucocorticoid biological responses at a dosage sufficient to prevent or reduce neurodegeneration. The progestin compound preferably comprises 16-methylene-17?-acetoxy-19-norpregn-4-ene-3,20-dione, and the methods include combining the progestin compound with an estrogen compound to provide both contraception and treatment for myelin repair and neurodegeneration, and include effects on stroke and TBI.Type: ApplicationFiled: December 21, 2012Publication date: May 9, 2013Applicant: THE POPULATION COUNCIL, INC.Inventor: The Population Council, Inc.
-
Patent number: 8425937Abstract: The invention relates to glucocorticoid replacement therapy and provides pharmaceutical compositions and kits designed to deliver one or more glucocorticoids to a subject in need thereof in a manner that results in serum levels of the glucocorticoid that essentially mimic that of a healthy subject for a clinically relevant period of time. The pharmaceutical composition comprises one or more glucocorticoids, wherein a first part of one or more glucocorticoids is substantially immediately released and a second part of one or more glucocorticoids is released over an extended period of time of at least about 8 hours, and the amount of the one or more glucocorticoids of the first part, expressed as hydrocortisone equivalents, is in a range of from about 15 to about 50% of the total hydrocortisone equivalents.Type: GrantFiled: April 21, 2005Date of Patent: April 23, 2013Assignee: DuoCort Pharma ABInventors: Stanko Skrtic, Jörgen Johnsson, Hans Lennernäs, Thomas Hedner, Gudmundur Johannsson
-
Patent number: 8426392Abstract: The invention provides a method for providing emergency contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate in an oral dosage form before, during or after a meal. The invention further provides a kit comprising i) an oral dosage form comprising ulipristal acetate and ii) a printed matter stating that ulipristal acetate may be taken with or without food.Type: GrantFiled: December 9, 2009Date of Patent: April 23, 2013Assignee: Laboratoire HRA-PharmaInventors: Erin Gainer, Henri Camille Mathe
-
Publication number: 20130089574Abstract: The invention relates to a method of hormonal female controlled on-demand contraception in which a pharmaceutical preparation comprising at least one progestogen is administered transdermally on demand and on a single occasion prior to anticipated sexual intercourse.Type: ApplicationFiled: May 29, 2012Publication date: April 11, 2013Applicant: Bayer Pharma AGInventors: Karin SCHMIDT-GOLLWITZER, Gunter STOCK
-
Patent number: 8415332Abstract: The present invention provides ascending-dose extended cycle regimens in which a female is administered an estrogen and a progestin for a period of greater than 30 or 31 consecutive days, optionally followed by a hormone-free period or by a period of administration of estrogen. The disclosed regimens can be administered to a female to provide contraceptive and non-contraceptive benefits.Type: GrantFiled: August 17, 2007Date of Patent: April 9, 2013Assignee: Teva Woman's Health, Inc.Inventors: Charles E. Diliberti, Kathleen Z. Reape, Lance J. Bronnenkant
-
Publication number: 20130078286Abstract: The subject invention provides a drug delivery system comprising at least one compartment consisting of (i) a drug-loaded thermoplastic polymer core, (ii) a drug-loaded thermoplastic polymer intermediate layer and (iii) a non-medicated thermoplastic polymer skin covering the intermediate layer, wherein said intermediate layer is loaded with (a) crystals of a first pharmaceutically active compound and with (b) a second pharmaceutically active compound in dissolved form and wherein said core is loaded with said second compound in dissolved form.Type: ApplicationFiled: November 9, 2012Publication date: March 28, 2013Applicant: MSD Oss B.V.Inventor: MSD Oss B.V.
-
Publication number: 20130079311Abstract: The invention provides compositions and methods for the convenient compounding of pharmaceuticals. Single and multiple unit of use kits are provided which contain all the necessary components required for preparing a compounded pharmaceutical. The kits of the invention include a first container having a first active agent and a second container having at least one second inactive agent. The kits of the invention are also useful for compounding veterinary pharmaceuticals.Type: ApplicationFiled: September 27, 2012Publication date: March 28, 2013Applicant: CutisPharma, Inc.Inventor: Indu Muni
-
Patent number: 8389502Abstract: Stabilized, 17-substituted hydrocortisone containing compositions and methods of manufacture are disclosed. Isomerization of the hydrocortisone component of topical steroid compositions is markedly reduced by including an omega-6 acid component in the form of a free acid or as a compound such as an ester. Specifically disclosed are methods for preventing the isomerization of hydrocortisone 17-butyrate into hydrocortisone 21-butyrate through the use of safflower oil.Type: GrantFiled: June 8, 2011Date of Patent: March 5, 2013Assignee: Precision Dermatology, Inc.Inventor: Pravin M. Patel
-
Publication number: 20130052263Abstract: Pharmaceutical compositions with synchronized solubilizer release as well as various methods associated therewith, are disclosed and described. More specifically, the aqueous solubility of a drug is enhanced by synchronized release of a solubilizer.Type: ApplicationFiled: October 29, 2012Publication date: February 28, 2013Applicant: LlPOCINE, INC.Inventor: LlPOCINE, INC.
-
Publication number: 20130045953Abstract: The invention discloses compositions and methods for ensuring in both women of fertile age where it ensures also a contraception with additional health benefits and in postmenopausal women where it offers a hormonal therapy with additional medical benefits such as the potential for lower risk of thrombosis. The aforementioned compositions comprising NES as a potent progestational and antiovulatory agent with no androgenic nor estrogenic nor glucocorticoid effect, and combined with estradiol formulated for non-oral transdermal administration as specific daily doses.Type: ApplicationFiled: December 17, 2010Publication date: February 21, 2013Applicants: ANTARES PHARMA IPL AG, THE POPULATION COUNCIL, INC.Inventors: Regine Sitruk-Ware, Dario Norberto Ramon Carrara, Arnaud Grenier
-
Publication number: 20130034500Abstract: The invention provides methods for decreasing or inhibiting herpesviridae (HV) infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with a herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).Type: ApplicationFiled: June 29, 2012Publication date: February 7, 2013Inventors: Paul B. Savage, Donald Y.M. Leung
-
Patent number: 8367646Abstract: The invention provides methods to treating conditions such as prostate cancer, or for ameliorating one or more symptoms associated with prostate cancer, or for agents that modulate the biological activity of the androgen receptor. The invention also provides methods and compositions suitable for therapeutic applications.Type: GrantFiled: November 29, 2011Date of Patent: February 5, 2013Assignee: Harbor Therapeutics, Inc.Inventor: James M. Frincke
-
Publication number: 20130029946Abstract: Embodiments of methods of treating atherosclerosis are described. In some embodiments an emulsifier is provided to achieve levels in the systemic circulation that are effective to solubilize atherosclerotic plaque, resulting in plaque regression. In some embodiments, levels of greater than 50 ?M are achieved; in some embodiments levels ranging from about 100 ?M to about 600 ?M are achieved; in some embodiments, levels ranging from about 100 ?M to about 300 ?M are achieved. Emulsifiers can include bile salts, saponins, and ionic, nonionic, and zwitterionic detergents, or salts, conjugates, hydrates, solvates, or polymorphs thereof. In some embodiments, a statin can be administered simultaneously or sequentially with an emulsifier.Type: ApplicationFiled: October 2, 2012Publication date: January 31, 2013Applicant: AtheraNova Operations, Inc.Inventor: AtheraNova Operations, Inc.
-
Publication number: 20130029947Abstract: The present invention provides for progesterone containing pharmaceutical oral dosage forms, pharmaceutical kits, and related methods. In one embodiment, an oral dosage form formulated for on-going administration is provided. The oral dosage form includes an amount of progesterone and a pharmaceutically acceptable carrier. The oral dosage form is formulated such that upon single dose administration to a non-pregnant woman in follicular phase, the oral dosage form provides a serum progesterone C24h of at least 0.20 ng/mL.Type: ApplicationFiled: October 4, 2012Publication date: January 31, 2013Applicant: LIPOCINE INC.Inventor: Lipocine Inc.
-
Patent number: 8361995Abstract: The present invention relates to the use of at least one gestagen selected from the group consisting of chlormadinone acetate, 3?-hydroxy-6-chloro-17?-acetoxy-4,6-pregnadien-20-one (3?-hydroxy-chlormadinone acetate) and 3?-hydroxy-6-chloro-17?-acetoxy-4,6-pregnadien-20-one (3?-hydroxy-chlormadinone acetate) as gestagen component and optionally at least one oestrogen selected from the group consisting of ethinyl oestradiol, oestrone, oestriol as oestrogen component and oestradiol to produce a medicament for the treatment and/or prevention of melasma and optionally for simultaneous hormonal contraception or optionally for simultaneous hormone replacement for women.Type: GrantFiled: September 3, 2009Date of Patent: January 29, 2013Assignee: Richter Gedeon Nyrt.Inventor: Georg Schramm
-
Publication number: 20130022674Abstract: A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed. Methods of treating a hormone deficiency or effecting male contraception with the inventive formulations are also provided.Type: ApplicationFiled: July 19, 2012Publication date: January 24, 2013Applicant: Clarus Therapeutics, Inc.Inventors: Robert E. Dudley, Panayiotis P. Constantinides
-
Publication number: 20130018022Abstract: The present invention relates to a pharmaceutical composition including a testis extract serving as an active ingredient for treating and preventing anemia, in which since the testis extract induces proliferation of hematopoietic stem cell, an increase in the number of red blood cell, and an increase in the amount of hemoglobin, it is effectively used as a therapeutic agent for treating anemia related to red blood cell and hemoglobin in women of childbearing age, post-childbearing age, and during pregnancy, as well as in men.Type: ApplicationFiled: April 22, 2010Publication date: January 17, 2013Applicant: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YEUNGNAM UNIVERSITYInventors: In-Ho Choi, Dong-Mok Lee, Eun-Ju Lee, Ki-Ho Lee, Yong-Pil Cheon, Tae-Hoon Chun
-
Patent number: 8349821Abstract: A stanol composition containing in addition to sitostanol as the main component, also a substantial amount of at least 10% campestanol has been found to effectively lower serum cholesterol levels when incorporated in edible commodities. Upon esterification the composition is especially useful in edible fats and oils and in fat-containing foods.Type: GrantFiled: March 25, 2010Date of Patent: January 8, 2013Assignee: Raisio Nutrition Ltd.Inventors: Ingmar Wester, Tapio Palmu, Tatu Miettinen, Helena Gylling
-
Patent number: 8349820Abstract: The invention relates to the use, optionally together with oral contraception, of estradiol valerate or 17?-estradiol in combination with 17?-cyanomethyl-17-?-hydroxyestra-4,9-dien-3-one (dienogest) in a multistage or single-stage combination preparation for oral therapy to maintain and/or increase feminine libido. The total number of daily dose units of the multistage combination and of a pharmaceutically harmless placebo or a single-stage combination and optionally the pharmaceutically harmless placebo-containing or placebo- and hormone-free daily dose units amounts to 28 daily dose units.Type: GrantFiled: October 17, 2007Date of Patent: January 8, 2013Assignee: Bayer Pharma AktiengesellschaftInventors: Susan Zeun, Holger Zimmermann, Susanne Parke
-
Patent number: 8349819Abstract: A process in which urine is optionally filtered to remove solid extraneous matter and optionally treated so as to reduce the phenolic content of the urine to give and the resulting fluid is then subjected to a solid extraction of the major concentration steroids content therefrom by a first suitable resin (to yield a first resin laden with major concentration steroids and a minor concentration steroid laden first liquid remainder). The minor concentration steroid liquid remainder is subjected to a solid extraction of the minor concentration steroid content therefrom by a second suitable resin (to yield a second resin laden with minor concentration steroids and a second liquid remainder). The first and second resins laden with their respective steroids are then eluted and the eluates are collected separately and optionally subjected to further purification and chromatographic separations, with each resulting separate collection being analyzed for the steroid content thereof.Type: GrantFiled: February 10, 2005Date of Patent: January 8, 2013Assignee: Dr. Reddy's Laboratories New York, Inc.Inventors: John Lomans, Carmen Leiva-paredes
-
Patent number: 8343965Abstract: Compositions, preferably pharmaceutical compositions, containing micronized tanaproget, or pharmaceutically acceptable salt thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, butylated hydroxyanisole, povidone, and magnesium stearate, are provided. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake.Type: GrantFiled: April 26, 2006Date of Patent: January 1, 2013Assignee: Wyeth LLCInventors: Arwinder S. Nagi, Ramarao Chatlapalli, Shamim Hasan, Rolland W. Carson, Mohamed Ghorab
-
Publication number: 20120329765Abstract: Aqueous phospholipid systems comprising at least one phospholipid, at least one bile acid and water are suitable for producing medicaments for the treatment of adipose tissue disorders and lead to regression of the pathologically proliferated adipose tissue.Type: ApplicationFiled: January 24, 2012Publication date: December 27, 2012Inventors: Peter Boderke, Rainer Pooth, Juergen Sandow, Matthias Gossel, Karl-Heinz Nietsch, Gerhard Sattler, Gerhard Vogel
-
Patent number: 8338396Abstract: This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.Type: GrantFiled: May 24, 2010Date of Patent: December 25, 2012Assignee: Teva Women's Health, Inc.Inventors: Robert G. Bell, Carole Ben-Maimon, Beata Iskold
-
Patent number: 8338395Abstract: Described are methods for providing prolonged physiologically acceptable steady state serum testosterone levels in a patient deficient in endogenous testosterone levels, methods for male contraception and methods for treating a disease or symptom associated with deficient endogenous levels of testosterone in a man, by intramuscularly administering testosterone esters in a vehicle.Type: GrantFiled: February 24, 2009Date of Patent: December 25, 2012Assignee: Bayer Intellectual Property GmbHInventors: Doris Hubler, Sabine Fricke, Jan-Peter Ingwersen, Wilheim Kuhnz
-
Publication number: 20120322777Abstract: This invention relates to a method of preventing pregnancy and treating PMS including PMDD. More particularly, the invention relates to a method, which involves administering one of several combination oral contraceptive regimens in combination with an antidepressant and a kit containing the same.Type: ApplicationFiled: August 30, 2012Publication date: December 20, 2012Inventors: Robert G. Bell, Carole Ben-Maimon, Beata Iskold
-
Patent number: 8329679Abstract: A method of producing a pharmaceutical preformulation in the form of a solid, free-flowing dry extract of a natural mixture of conjugated equine estrogens, which is particularly suitable use in for solid galenic forms, e.g. tabletting. The conjugated estrogens are available for further galenic processing in a form which assures the chemical stability of the hormones and permits advantageous processing into solid galenic forms, for example a tablet.Type: GrantFiled: May 30, 2012Date of Patent: December 11, 2012Assignee: Abbott Products GmbHInventors: Bernd Thumbeck, Ingo Bonnacker, Martina Lerch
-
Publication number: 20120309722Abstract: The invention features pharmaceutical compositions and dosing regimens for the treatment of immunoinflammatory disorders.Type: ApplicationFiled: August 16, 2012Publication date: December 6, 2012Inventor: Mahesh Padval
-
Patent number: 8324192Abstract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.Type: GrantFiled: November 9, 2006Date of Patent: December 4, 2012Assignee: The Regents of the University of CaliforniaInventors: Ranjan Dohil, John Bastian, Seema S. Aceves
-
Publication number: 20120289487Abstract: This invention refers to pharmaceutical use of multicyclic compounds chosen from ingenols, lanosta-8,24-dien-3-ols and their mixtures, as anti-AIDS agents.Type: ApplicationFiled: January 15, 2010Publication date: November 15, 2012Applicant: AMAZÔNIA FITOMEDICAMENTOS LTDAInventors: Luiz Francisco Pianowski, Joao Batista Calixto, Claudio Paulino Chaves
-
Publication number: 20120289486Abstract: A method for the treatment of eyelid dermatitis and/or dermatitis of the periorbital area is provided.Type: ApplicationFiled: May 10, 2011Publication date: November 15, 2012Inventor: Nicholas S. BODOR
-
Patent number: RE43916Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17?-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.Type: GrantFiled: March 24, 2006Date of Patent: January 8, 2013Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Jurgen Spona, Bernd Dusterberg, Frank Ludicke
-
Patent number: RE44159Abstract: A combination product for oral contraception is disclosed comprising an estrogen selected from 2.0 to 6.0 mg of 17?-estradiol and 0.020 mg of ethinylestradiol; and a gestagen selected from 0.25 to 0.30 mg of drospirenone and 0.1 to 0.2 mg of cyproterone acetate, followed by 5 or 4 pill-free or sugar pill days.Type: GrantFiled: August 28, 2007Date of Patent: April 16, 2013Assignee: Bayer Schering Pharma AktiengesellschaftInventors: Jurgen Spona, Bernd Dusterberg, Frank Ludicke